Oncology Logic Collaboration Senti's gene circuit platform enables logic-gated cell therapies with SENTI-202 for oncology; potential clients are cancer biotech and pharma firms seeking smarter, controllable therapies. Propose licensing, co-development, or collaborative research arrangements to bring logic-gated constructs into preclinical and clinical programs.

Strategic Funding Signals Recent strategic investment from Celadon Financial Group with a majority stake signals availability of capital for collaboration and licensing deals. Engage Celadon-backed portfolios and other investors for co-development funding and exclusive licensing to scale the platform.

Conference-Driven Partnerships Senti's active presence at industry events (AACR, Cell & Gene Live, Healthcare Conference Taipei, genetic medicines forums) creates ready avenues for partner discussions, pilots, and collaboration deals; arrange targeted demonstrations and scientific deep-dives with interested teams.

Regulated Editing Synergy Investments and collaborations around drug-inducible control circuits and regulated editing (RSRT partnerships, base editor programs) show demand for safety and control in gene editing. Target gene-editing platforms and clinical programs for co-development of inducible circuits or licensing opportunities.

Mid-Stage Partnering With a mid-market profile and revenue in the early range, Senti is well suited to engage biotech startups, CROs, and academic spinouts with pilot programs, phased licensing, or service-based collaborations to accelerate preclinical-to-clinical programs.